Stephen Gitelman

15PUBLICATIONS
67CO-AUTHORS
Gene and molecular therapyPacific Peoples theory of change models for healthMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Infant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 11, 2026
Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes.

|Sep 10, 2026
Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial.

|Mar 12, 2026
Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset.

Carmella Evans-Molina, Stephen E Gitelman, Andrea Mari

|Jan 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Carla J Greenbaum, S Alice Long, Stephen E Gitelman

|Nov 06, 2025
Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.

Stephen E Gitelman, Kimber Simmons, Jennifer L Sherr

|Feb 14, 2025
Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.

Holly K O'Donnell, Kimber M Simmons, Stephen E Gitelman

Pageof 3

Frequent Collaborators

5 joint publications

Kevan C Herold

5 joint publications

Kimber Simmons

5 joint publications

Linda A DiMeglio

4 joint publications

Carmella Evans-Molina